PersonalAIze and RenovaroCube announce a strategic partnership to develop, validate, and commercialize Cube’s AI-driven, multi-omic platform for early detection of cancer and other diseases. This strategic partnership aims to provide services to many AI companies and healthcare systems while also creating the next generation of medical diagnostics through cutting-edge AI by driving greater accuracy, transparency, and trust in healthcare solutions. Prof. Mark Hoogendoorn, Co-CEO and Co-Founder PersonalAIze: “The strategic partnership between PersonalAIze and Cube has the potential to provide a transformative leap in healthcare diagnostics, uniting cutting-edge AI with trusted, high-performance capabilities and industry related in-depth expertise.”
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RENB:
- PersonalAIze conducted evaluation on Renovaro’s RenovaroCube
- Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection
- RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress
- Renovaro BioSciences to present cancer diagnostics research at ESMO Congress
- RenovaroCube announces offering of up to 20% ownership